On November 1, 2024, Director Ramiro Guerrero purchased 88,534 shares of MAIA Biotechnology Inc (MAIA, Financial) at a price of $2.51 per share, as reported in the SEC Filing. Following this transaction, the insider now owns a total of 408,134.04 shares in the company.
MAIA Biotechnology Inc is a biotechnology firm focused on the development of targeted therapies for oncology. The company's approach includes innovative treatments that are designed to address significant unmet medical needs in the treatment of cancer.
The recent purchase by the insider is part of a broader trend observed over the past year, where there have been 11 insider buys and no insider sells. Over the past year, Ramiro Guerrero has increased his holdings by 95,462 shares in total, indicating a strong belief in the company's future prospects.
Shares of MAIA Biotechnology Inc were trading at $2.51 on the day of the transaction, giving the company a market cap of approximately $69.027 million. This valuation reflects the company's current GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This insider buying activity may be of interest to current and potential investors, as insider transactions can provide insights into how the company's top executives view the stock's value and future performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
